An innovative molecular detection platform utilizing microfluidic PCR technology capable of completing nucleic acid rapid detection within 30 minutes with high sensitivity and high specificity. The reagents are stable at room temperature without requiring cold chain storage, support customized multi...
Manufactured by
China
Xenta Biomedical Science Co., Ltd, founded in December 2021 and headquartered in Guangzhou Development District, is a national high-tech enterprise focused on the R&D, registration, and commercialization of in vitro diagnostic (IVD) reagents and devices. With fully paid-up capital of RMB 10 million, the company is led by a team of returnee PhDs with strong international research and industry experience. It is dedicated to developing innovative POCT technology platforms under the philosophy of "Faster, Better, and More Accessible". The company drives innovation through R&D centers in Guangzhou, Xiamen, and overseas. Using its proprietary dry light-excited chemiluminescence POCT platform, it has developed leading product series and managed major national research projects. The company has published over 20 SCI papers, holds 70 patents, has obtained more than 60 EU CE certifications, and 12 FDA approvals in the United States. Currently, several product lines are actively striving for NMPA certification. Its pipeline covers key areas including cardiovascular, inflammation, oncology, hormone, and infectious diseases, demonstrating end-to-end capabilities from R&D to global commercialization. The core team comprises graduates from top universities such as Texas A&M University, Xiamen University, Sanford-Burnham Medical Research Institute, and Sun Yat-sen University, possessing multidisciplinary expertise in biomedicine, engineering, and law. The co-founders have extensive experience from leading IVD companies, having previously guided teams to achieve annual revenues exceeding several hundred million yuan and secure over 200 product certifications worldwide. Since its establishment, Xenta Biomedical Science Co., Ltd has raised tens of millions in funding and obtained ISO 13485 certification, supporting its global expansion.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Sciverse Solutions
India · 2 relevant products
Guangzhou Wondfo Biotech Co., Ltd.
China · 1 relevant product
Planet Innovation Pty Ltd.
United States · 1 relevant product
Cambrian Bioworks LLC
United States · 1 relevant product
Shanghai Beion Medical Technology Co.,LTD.
China · 1 relevant product
Origin Biotechnology Co., Ltd.
Taiwan · 2 relevant products
BiOligo Biotechnology CO., LTD
China · 1 relevant product
Yaneng BIOscience (Shenzhen) Co.,Ltd.
China · 1 relevant product
Suzhou welgwiyan Precision Technology Co.,Ltd
China · 1 relevant product
Bioscience (Tianjin) DiagnosticTechnology Co.,Ltd
China · 1 relevant product
38 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 59 closest product alternatives
Sciverse Solutions · India
A portable molecular diagnostics system featuring a disposable microfluidic cartridge for closed-system nucleic acid testing with zero cross-contamination. The platform supports up to 32-plex multiplexing, delivers results in 45 minutes, and is available in handheld and benchtop configurations with customizable assays including a ready-to-deploy COVID-19 panel.
Guangzhou Wondfo Biotech Co., Ltd. · China
Molecular diagnostics platform for nucleic acid detection and amplification-based testing. Enables identification of pathogens and genetic markers for infectious disease and other molecular-based diagnoses.
Planet Innovation Pty Ltd. · United States
A low-cost point-of-care and at-home molecular diagnostic platform utilizing isothermal RT-LAMP and CRISPR-mediated detection without requiring sample purification steps.
Cambrian Bioworks LLC · United States
Automated platform for molecular diagnostics of infectious pathogens. Integrates nucleic acid extraction and amplification for rapid disease identification.
Shanghai Beion Medical Technology Co.,LTD. · China
Molecular analysis system for detection of nucleic acids and genetic material. Enables identification of pathogens, genetic mutations, and infectious agents at molecular level.
Origin Biotechnology Co., Ltd. · Taiwan
A molecular detection technology platform designed for rapid and accurate genetic screening and diagnosis. The system focuses on identifying hereditary and genetic diseases with clinical applications in prenatal and pediatric care.
BiOligo Biotechnology CO., LTD · China
Integrated molecular diagnostics platform providing oligonucleotide synthesis, validation, and custom kit development for life science research and clinical applications. The platform supports batch planning with consistent final yields and reduced reorder requirements.
Yaneng BIOscience (Shenzhen) Co.,Ltd. · China
Rapid HPV detection platform compatible with common PCR instruments, delivering results within 1.5 hours and enabling efficient cervical cancer screening in clinical settings.
Suzhou welgwiyan Precision Technology Co.,Ltd · China
Automated molecular detection systems utilizing microfluidic technology for nucleic acid and protein analysis. These systems integrate sample preparation, amplification, and detection in a single microfluidic platform.
Bioscience (Tianjin) DiagnosticTechnology Co.,Ltd · China
Molecular diagnostics platform for infectious disease identification and confirmation. Utilizes proprietary technology for rapid and accurate pathogen detection.
Origin Biotechnology Co., Ltd. · Taiwan
An advanced molecular medicine platform providing fast and precise detection of genetic markers and disease indicators. The technology addresses unmet clinical needs in genetic disease screening and diagnosis.
Shenzhen Diasia Biomedical Technology Co.,Ltd · China
A molecular diagnostic platform for nucleic acid detection and analysis in clinical laboratory settings. Provides results for infectious disease and genetic testing applications.
47 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products